PTGS2 and non-small cell lung carcinoma: However, although current evidence indicates that the COX-2 inhibitor is widely considered as an ancillary drug that can be combined with different anticancer treatments for advanced NSCLC, there is no evidence that treatment of advanced NSCLC with celecoxib alone has a better clinical benefit than the combination treatment.